Roche flunks its first-line degrader test
Persevera is a bust, but Roche hasn’t given up on the front line.
Betta joins Revolution in pan-RAS inhibition
BPI-572270 enters clinical trials.
Servier makes a rare big buy
The company pays $2.5bn for Day One and its approved drug Ojemda.
J&J receives Tecvayli/Darzalex nod
But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
Like Sanofi, German Merck keeps the CEACAM5 faith
Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
Ono chases Takeda in polycythemia
Ono's antisense therapy is to begin its first pivotal trial.
Revolution’s big reveal approaches
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
Double trouble for Incyte in KRAS
A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
Merck also goes for all-comers in adjuvant lung
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
